Koenraad Vandewoude, MD

Slides:



Advertisements
Similar presentations
Management of Inpatient Hyperglycemia in Special Populations
Advertisements

1 Using an External Control to Evaluate the Effectiveness of Posaconazole for Refractory Invasive Fungal Infections Kenneth J. Koury Jagadish P. Gogate.
2004 ISHLT J Heart Lung Transplant 2004; 23: HEART TRANSPLANTATION Pediatric Recipients.
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:
Infections in non-myeloablative « Reduced intensity conditioning » stem cell transplant Catherine CORDONNIER Hôpital Henri Mondor, Créteil, France.
Diagnosis of pulmonary aspergillosis (ignoring allergy)
Chronic pulmonary aspergillosis
Epidemiology and Outcomes of IA in the 21st Century: Strengths and Weaknesses of Surveillance Databases Dionissios Neofytos, MD, MPH Transplant & Oncology.
Fungal infections in COPD
Aspergillosis in AIDS David W. Denning
Update on Antigen Detection Paul E. Verweij, MD Nijmegen University Center for Infectious Diseases s Eukaryotic cell 2005;4:
Prevention of Ventilator Associated Pneumonia
Lecture 3 Validity of screening and diagnostic tests
Treatment of Fungal infections in Hematologic Malignancies
HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.
How do we delay disease progress once it has started?
Roswell Park Cancer Institute
Infection in COPD Pulmonology Subspeciality Rounds (12/11/2008)Dr.Krock Dr.Vysetti Dr.Vysetti.
ARE CAP AND HCAP TWO SEPARATE ENTITIES? Francesco Blasi Department Pathophysiology and Transplantation, University of Milan, Italy.
University of Minnesota – School of Nursing Spring Research Day Glycemic Control of Critically Ill Patients Lynn Jensen, RN; Jessica Swearingen, BCPS,
OPPORTUNISTIC FUNGAL INFECTIONS
The times.. they are a changing Dr. Hamdi Akan Ankara University Medical School Dept. of Hematology.
Fungal Infection in the ICU
Initial Antifungal Therapy for Critical Ill Patients When and Which ? 林口長庚 胸腔內科 林鴻銓 Lin, Horng-Chyuan Division of Pulmonary Infectious & Immunological.
بسم الله الرحمن الرحيم Medical mycology
The changing epidemiology of invasive aspergillosis Wouter Meersseman, MD, PhD University Hospital Gasthuisberg General Internal Medicine Leuven 08 Nov.
Lower Respiratory Tract Infection. Pneumonia Common with high morbidity and mortality rates. Acute respiratory infection with focal chest signs and radiographic.
Interaction of Aspergillus with the host A unique microbial-host interaction Immune dysfunction Frequency of aspergillosis Immune hyperactivity Frequency.
The Nature of Disease.
Estimating the Burden of Serious Fungal Diseases in Thailand Methee Chayakulkeeree 1, David W. Denning 2* 1 Division of Infectious Diseases and Tropical.
Antifungal therapy: Polyenes, posaconazole, or prayers Michael Kleinberg, MD, PhD Associate Professor of Medicine Head, Infectious Diseases Section Marlene.
Part I BACKGROUND VENTILATOR ASSOCIATED PNEUMONIA.
ARDS: how are we doing? Martin Hughes September 2010.
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Aspergillosis Slide Set Prepared by the AETC.
Life-Threatening Infections: Diagnosis and Antimicrobial Therapy Selection.
Opportunistic Pathogens –Aspergillus species. Aspergillosis is an infection caused by Aspergillus, a common mold that lives indoors and outdoors. Most.
Pneumonia Egan’s Chapter 22. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Introduction Infection involving the.
Mini BAL v/s Bronchoscopic BAL PROF. PRADYUT WAGHRAY MD (CHEST), DTCD, FCCP (USA),D.SC(PULM. MEDICINE) HEAD OF DEPT. OF PULMONARY MEDICINE S.V.S MEDICAL.
Hospital-acquired Invasive Aspergillosis: How Big is the Problem?
Lateral flow device (LFD) test on bronchoalveolar lavage (BAL) samples for diagnosing invasive pulmonary aspergillosis (IPA): diagnostic accuracy Single-centre.
Tuberculosis in Children and Young Adults
Nosocomial infection Hospital acquired infections.
RESPIRATORY FUNGAL INFECTION. YEASTMOULD FUNGIDIMORPHIC FUNGI OpportunisticPrimary Infectious Candidiasis (Candida and other yeast) Aspergillosis (Aspergillus.
Respiratory Fungal Infections
R3 정수웅. Introduction Community-acquired pneumonia − Leading infectious cause of death in developed countries − The mortality in patients with treatment.
Spectrum of Radiologic Findings for Pulmonary Aspergillosis X. Gallardo, E. Casta ñ er, J.M. Mata, F. Novell, M. Andreu.
Nosocomial infection Hospital acquired infections.
PANDHARIPANDE PP ET AL. N ENGL J MED 2013; 369: Long-Term Cognitive Impairment after Critical Illness.
폐렴으로 오인할 수 있는 폐렴 외 질환 호흡기 내과 R3 최 문 찬.
Depart. Of Pulmonology and Critical Care Medicine R4 백승숙.
Timothy W. Felton, Caroline Baxter, Caroline B. Moore, Stephen A.Roberts, William W. Hope,and David W. Denning Clinical Infectious Diseases 2010; 51:1383–1391.
Prepared by the AETC National Coordinating Resource Center based on recommendations from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious.
Comparison between pathogen directed antibiotic treatment and empiri cal broad spectrum antibiotic treatment in patients with community acquired pneumonia.
Time for first antibiotic dose is not predictive for the early clinical failure of moderate–severe community-acquired pneumonia Eur J Clin Microbial Infect.
APIC Chapter 13 Journal Club March 16, 2015 Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults NEJM – July 30, :5 Presented.
A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis B. M. Fischer1,
Multifocal Consolidation with Halo Sign 경희대학교 의과대학 감염내과 박기호.
King’s College Hospital, London, UK
Respiratory diseases caused by fungi
Pneumonia Salutations:
Relationship between CMV & PU disease
Hospital acquired infections
Respiratory Fungal Infections
8th Advances Against Aspergillosis international conference
Chronic Pulmonary Aspergillosis
Intra-Abdominal Candidiasis, Candida peritonitis
8th Advances Against Aspergillosis international conference
بنام خداوند جان و خرد بنام خداوند جان و خرد.
Ordering Sputum Cultures in Community Acquired Pneumonia
Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients  D. Caillot, L. Mannone,
Presentation transcript:

Invasive Aspergillosis in Critically Ill Patients A New 21th Century Problem? Koenraad Vandewoude, MD Intensive Care Dpt. – Solid Organ Transplant Centre Ghent University Hospital Ghent, Belgium

Invasive Aspergillosis Extensive data available in distinct high-risk patient populations: Hemato-oncological patients Allogeneic SCT, graft-vs.-host disease Persistant neutropenia Solid organ transplant patients, >> lung Immunosuppressive therapy Chronic granulomatous disease Severe combined immunodeficiency HIV …

Aspergillus spp. Underestimated Pathogen in the ICU? Epidemiological data on incidence and outcome of Invasive Aspergillosis in Critically Ill patients are scarce … Low index of suspicion Positive cultures often discarded as colonization or contamination Absence of feasible diagnostic reference standard Now, the question addressed in this lecture, is whether Aspergillus is an underestimated pathogen in critically ill patients? What we know for sure, is that reliable data on the incidence of invasive aspergillosis in this setting are scarce. Several factors may explain this lack of data. First, the index of suspicion of this opportunistic infection is still low amongst critical care practioners. Respiratory tract samples positive for Aspergillus are often discarded as colonization or contamination, and are not taken into account for treatment. Moreover, in contrast to immunocompromised host, there is no feasible and reliable diagnostic reference standard. And finally, in order to have a good estimate of incidence of this disease, a per protocol necropsy policy is necessary in patients dying with unexplained pneumonia.

Invasive Pulmonary Aspergillosis in Critically Ill patients Differentiate between Pts referred to the ICU with IPA e.g. pt. from Bone Marrow Transplant Unit with proven/probable IPA and respiratory failure 100% mortality? 1 Pts. with IPA diagnosed in the ICU community acquired nosocomial ICU acquired grim prognosis 2 Of course, one should make a difference between patients, admitted to the ICU, referred from the bone marrow transplant unit with an established diagnosis of aspergillosis. It is known that when such a patient develops respiratory insufficiency, death is impending, and mortality is nearly 100%. On the other hand, there are group of critically ill patients, in whom the diagnosis of invasive pulmonary aspergillosis is made during their ICU stay. They may have acquired the disease in the community, or during there stay in other wards of the hospital, including in the intensive care; studies about health care associated pneumonia have demonstrated that also in this group of patients, the outcome of nosocomially acquired IA is very poor, with a mortality of about 80%. Janssen JJ. Outcome of ICU treatment in Invasive Aspergillosis. Intens Care Med 1996; 22: 1291-93 Vallés J. A 7 year Study of Severe Hospital Acquired Pneumonia requiring ICU Admission. Intens Care Med 2003; 29: 1981-88

Pulmonary Aspergillosis A Spectrum of Clinical Entities Depending on patient immune status With tissue invasion 1,2 Acute invasive aspergillosis Subacute invasive aspergillosis Chronic cavitary and fibrosing pleuropulmonary aspergillosis Acute Tracheobronchitis with tissue invasion Without tissue invasion Tracheobronchial colonization Tracheobronchitis Pulmonary Aspergilloma The term invasive aspergillosis, refers to several categories of disease; the severity of disease is mainly dependent upon the host immune defence. Aspergillosis may present as an acute pneumonia, with hefty tissue invasion, leading to demise in 7 to 10 days, even when treated appropriately. However, there also exist more indolent forms of aspergillosis, that evolve over weeks and even months, and that are accompanied with less or more severe systemic and respiratory signs and symptoms. A special entity of invasive pulmonary aspergillosis is acute invasive aspergillus tracheobronchitis. This form of the disease is chararacterized by ulcerative lesions in the tracheobronchial tree, and by the formations of membranes – these membranes may ultimately obstruct the airways, leading to respiratory insufficiency; most patients have severe bronchoconstriction, and mechanical ventilation is very difficult with high ventilatory pressures. On the other end of the disease spectrum, are entities without evidence of tissue invasion: such as innocent colonization of the airways (frequently seen in COPD patients and smokers, non invasive bronchits, and the pulmonary aspergilloma, developing in a pre-existing cavity, with the development of hyphae in that cavity, but without evidence of tissue invasion. Clinical entity may change due immune defence alteration 1 Denning DW. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis. Clin Infect Dis 2003 2 Paterson DL. New clinical presentations of invasive pulmonary aspergillosis in non-conventional hosts. Clin Microbiol Infect 2004

IPA diagnosis in ICU patients EORTC/MSG Case Definitions 1 Difficult to apply outside high risk populations Not useful to guide therapy One of the major problems in ICU patients, is the absence of a reliable diagnostic reference frame. One can argue that is would be feasible to use the EORTC/MSG diagnostic criteria for invasive mould infections – but in fact these guidelines are not applicable outside the severely immunocompromised population; furthermore, these guidelines should not be used to guide therapy and clinical practice – if so, antifungal treatment would be instituted late in the course of the disease, or would not even be considered. 1 Ascioglu S. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants. Clin Infect Dis 2002

Consensus Definitions Proven IPA Histopathology + culture Probable IPA 1 host + 1 microbiological +1 clinical Host: neutropenia, fever, immunosuppressive therapy, steroids, GVHD Microbiological: positive culture sputum, BAL Non-invasive test: galactomannan, -D-glucan CT: halo, air-crescent, cavity within area of consolidation Possible IPA 1 host + 1 microbiological OR 1 clinical More specific signs / symptoms CT: halo, air-crescent, cavity New infiltrate + specific pulmonary: pleural rub; pleural pain; hemoptysis The consensus definitions are well known, and are based upon host risk factors, the results of microbiological examination, and the clinical picture, including the results of medical imaging. Non-invasive markers, such as the galactomannan and glucan, and PCR, in blood or bronchial lavage fluids, can also be used to substantiate the diagnosis. Probable and possible aspergillosis are the most frequent clinical categories of diagnosis in routine practice.

Particular Issues in ICU patients Interpretation of Host Factors: not always clearly detectable … (combination of) underlying disease and/or critical illness induced immunosuppression with low or intermediate probability of invasive disease 1, 2 Impaired phagocytic function Organ dysfunctions, metabolic derangements Corticosteroids 3, 4: difficult assessment of treshold dose/duration of exposure* However, one should consider some particular issues in the critical care setting. Firstly, the interpretation of host factors is not evident in ICU patiens. These can be easily appreciated in patients referred by the hematology ward, but how should we appreciate the temporary immune deficiency, or immunoparalysis, that can occur after sepsis and during severe critical illness? This immunocompromised state is characterized by deficient phagocytosis, and both innate and acquired immune dysfunctions; a patient immune defence may be further weakenen by multiple organ dysfunction, and metabolic derangements, such as uremia, liver dysfunction, and hyperglycemia Furthermore, corticosteroid therapy is frequently given to septic patients and in case of COPD exacerbations. It not clear at what dose this kind of treatment should be considered as a major host risk factor – it also known that hydrocortisone enhances the growth of Aspergillus fumigatus in vitro. 1 Hartemink KJ. Immunoparalysis as a cause for invasive aspergillosis? Intensive Care Med 2003 2 Engelich G. Acquired disorders of phagocyte function complicating medical and surgical illnesses. Clin Infect Dis 2001 3 Lionakis M. Glucocorticoids and Invasive Fungal Infections. Lancet 2003; 362: 1828-38 4 Palmer LB. Corticosteroid Treatment as a Risk Factor for Invasive Aspergillosis in Patients with Lung Disease. Thorax 1991; 46: 15-20

Particular Issues in ICU patients Signs and symptoms difficult to appreciate cough, chest pain, pleural rub, hemoptysis, dyspnea non specific evaluation difficult or impossible fever? clinical examination hampered by mechanical ventilation A second problematic issue is the assessment of clinical signs and symptoms; in patients that are intubated and sedated. One can not rely on fever, as a warning symptom as in the setting of neutropenia; furthermore, clinical examination is hampered by the supportive treatment patients receive on the ICU.

Particular Issues in ICU patients Medical Imaging: Concurrent pulmonary injury hampers interpretation residual infiltrates, atelectasis, ARDS, … CT scan feasible in case of high-grade ventilatory and inotropic dependency? Typical lesions: Halo, Air-crescent … low incidence in non-neutropenic patients Another problem is the value of medical imaging. There are so many confounding factors in the interpretation of radiological data, such as residual infiltrates after bacterial pneumonia, atelectasis, pleural fluid effusion, ; Specific features such as the halo sign and the air crescent sign are infrequently seen in ICU patients, moreover it has been shown that this radiological features ar far less common in patients with other immune deficiencies than neutropenia; Greene RA. Radiologic findings in acute invasive pulmonary aspergillosis: utility of the halo and air-crescent sign for diagnosis and treatment of invasive pulmonary aspergillosis in high-risk patients. 13th ECCMID, 2002, Glasgow

Microbiological sampling … >> lower respiratory tract samples BAL not always feasible Direct microscopy is mandatory!* Serology Aspergillus galactomannan? ** validation in neutropenic pts sensitive/significant in other patients ß-glucan: ? *** Biopsy procedures … transbronchial biopsy not possible thoracoscopic procedure preferred caveats: ventilator and pressor dependency coagulation disorders … The interpretation of microbiological data is also difficult. Broncho-alveolar lavage is not always feasible An important point is always to require for an urgent direct microscopic examination: the demonstration of septate hyphae may be a key indicator for the diagnosis. There is a lot of experience with non-invasive diagnostics such as the galactomannan test, and the demonstration of the beta D glucan, in patients after stem cell transplantation, but the sensitivity and specificity of these test in other patient groups should be further explored. Finally, one could argue to be more aggressive in diagnostic procedures and to have a lung tissue biopsy in case of diagnostic incertitude, however, such quite invasive procedures are often not possible in patients with high grade ventilatory and inotropic support, and in the presence of coagulation abnormalities. Moreover, biopsy can be falsely negative due to sampling error, or after exposure to antifungals. * Uffredi ML. Significance of aspergillus fumigatus isolation from respiratory specimens in non-granulocytopenic patients. Eur J Clin Microbiol Infect Dis 2003 * * Maertens J. Screening for circulating galactomannan as a non-invasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients. Blood 2001; 97: 1604-10 ** *Ostrosky-Zeichner L. Multicenter clinical evaluation of the (1-3) beta-D-glucan assay as an aid in diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9

Invasive Aspergillosis in ICU Patients Fact or Fiction? Isolation of Aspergillus spp. in ‘immunocompetent host’ is often/always interpreted as colonization …. Assessment of clinical signifance most difficult in patient groups with intermediate risk of invasive disease Literature data Variable diagnostic criteria When you have a positive culture in a patient, a major problem is to estimate the clinical significance of this finding, in patients with an intermediate or low probability of acquiring invasive pulmonary aspergillosis. Differentiating between colonization and infection is a major challenge for the clinician. When reviewing the available literature, there is also some differences in the diagnostic assessment of patients.

of Aspergillosis. Clin Infect Diseases 2001 In the setting of stem cell transplantation, it is quite evident to state that a positive culture is clinically relevant, because more then 60 % of these patients do have invasive disease, But the problem is an accurate interpretation of a culture in patients with intermediate risk for aspergillosis, certainly when it concerns patients with non hematological disease, such ase malnutrition, diabetes, chronic lung disease. This has been nicely demonstrated in this paper by Perfect. Perfect J. Impact of culture isolation of Aspergillus species: a hospital-based survey of Aspergillosis. Clin Infect Diseases 2001

Author Year Type of study Patient category N. Incidence Mortality Lewis 1985 Case series IPA complicating influenza pneumonia Case report and literature review 6 - 100% Karam 1986 Cases series Non-neutropenic patients - 10 structural lung disease 7 steroid treatment 32 Janssen JJWM 1996 Monocentric Retrospective Medical ICU pts with hematological malignancy, immunosuppression for mixed connective tissue disease, ARDS 25 92% Pittet COPD patients in MICU Acquisition of IPA during mechanical ventilation due to high grade airborne inoculation 2 Rello 1998 Series of COPD patients and literature review 24 Valles 2002 Two centres Observational, prospective study Hospital acquired pneumonia requiring ICI admission Aspergillus spp. identified in 17% of pts Mainly COPD pts 77% Bulpa 2001 COPD patients admitted to ICU diagnosed with IPA 23 Meersseman 2004 Medical ICU 70% cases without malignancy 5 pts with IA without known predisposing condition (of whom 3 Child C cirrhosis) 107 5.8% 91% Garnacho-Montero 2005 Multicentric Prospective 73 ICU’s in Spain patients with LOS > 7 days 20 1.1% 80% Vandewoude 2006 Mixed ICU 40% haematological pts 83 3.3/1000 Now, what about the available literature on invasive aspergillosis in ICU patients? This form of the disease has already been identified more than twenty years ago, as a major complication in patients with existing structural lung disease, and as a complication of influenza pneumonia, as described by Karam and Lewis in the eighties. Case series have also indicated that Aspergillus must be considered as pathogenic in patients with COPD, one should be very alert in these patients if they had exposure to corticosteroid treatment even in low doses and for short courses. In a Dutch study, ICU treatment for hematological patients with invasive aspergillosis was considered futile, because of the high mortality. Bulpa described a series of COPD patients with invasive disease, and also raised the question of therapeutic futility because of poor outcome of these patients. Finally, there are three studies in intensive care, adressing epidemiologic features of pts with IA.

Invasive pulmonary aspergillosis in non-immunocompromised, non-neutropenic hosts* Review of 32 cases Underlying diseases: lung fibrosis, COPD, Influenza A, diabetes mellitus, alcoholism, ‘short’ course of steroids, … … IPA should be considered when Aspergillus spp. is isolated in resp. secretions and presence of pneumonia …. * Karam G. Invasive pulmonary aspergillosis in non-immunocompromised, non-neutropenic hosts. Reviews of infectious diseases 1986; 8: 357-63

COPD patients with IPA: benefits of ICU? * 23 pts, 16 proven, 7 probable (repeated isolation) recent steroid treatment, or intensification of steroid treatment severe bronchospasm (12/23) all required mechanical ventilation Mortality 100% This slide refers to the paper of Bulpa, describing a series op 23 patients with COPD and invasive aspergillosis; All these pts developed respiratory insufficiency requiring mechanical ventilation, and all of them died. * Bulpa P. COPD patients with invasive pulmonary aspergillosis: benefits of intensive care? Intens Care Med 2001; 27: 59-67

Invasive pulmonary aspergillosis in COPD patients: an emerging fungal pathogen* 13 cases of IPA in COPD pts admitted to ICU bronchospasm ++ steroid treatment often continued in spite of isolation of Aspergillus spp. Mortality 100% - proven IPA by autopsy In a recent paper by Ader, the importance of Aspergillus as a lethal pathogen in COPD was highlighted; it was stressed Aspergillus isolation should be considered relevant, after steroid treatment An important observation in this study, and also in the previous study , is the presence of severe bronchoconstriction, impeding mechanical ventilation in these patients. * Ader F. Invasive pulmonary aspergillosis in COPD patients: an emerging fungal pathogen. Clin Microbiol Infec 2005: Jun;11:427-9.

Retrospective cohort study based on prospectively gathered microbiology and autopsy data – UZ KULeuven: 127/1850 ptn An excellent study from Leuven has learned us important data about invasive aspergillosis in patients in a medical ICU In this study, EORTC guidelines were strictly applied, and they performed autopsy in 76 patients out of 127 patients with suspicion of invasive aspergillosis. The diagnosis of invasive aspergillosis was made in 107 patients, representing an incidence of more than 5%; the majority of the patients did not suffer from hematologic disease. The mortality of more than eighty percent, and exceeded the mortality as derived from the SAPS score upon admission of these patients, indicating the serious impact of aspergillosis on patient outcome. 5.8% van aantal opgenomen ptn!!! met IPA Meersseman W. Invasive Aspergillosis in Critically Ill patients without Malignancy Am J Respir Crit Care Med 2004

In a Spanisch multicenter study, the incidence of Invasive disease was about 1.1 % of admissions; Only 10 % of patients had neutropenia as predisposing factor COPD was the major underlying illness in these patients, and most of them received corticosteroid treatment; Mortality was 80%

Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Critical Care 2006 Retrospective study 1997-2003 Sole entry criterion = positive lower respiratory tract specimen Adapted criteria to discriminate colonization vs. clinical relevant ‘infection’ (i.e. : relevant to start antifungal treatment) Incidence 3.3/1000 admission

Adapted Diagnostic Criteria … Definite IPA positive histology (+culture) of lung tissue positive culture from normally sterile site Probable IPA Lower resp tract sample pos for Aspergillus Compatible signs and symptoms Abnormal medical imaging of chest Either host risk factors: neutropenia, hemato-oncologic malignancy treated with cytostatics, steroid treatment > 20 mg/day, immunodeficiency BAL: semiquantitative positive culture +/++ and cytologic exam positive (branching hyhae) We performed a retrospective study in ICU patients, with as sole entry criterion a positive culture of Aspergillus in a respiratory specimen, and we used adapted criteria to discriminate colonization from infection The criteria were adapted, in a way that we took any evidence of pneumonia into account, and that we considered to presence of a clearly positive microscopic evidence, with septate hyphae, as an information that corroborates the clinical relevance. Vandewoude K. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Critical Care 2006

We had 172 pts with a positive culture, and according to the diagnostic algoritm, we could separated two groups of patients, group of pts with IA and another considered as colonization, because of the absence of pneumonia, host risk factors, and because the positive culture was not supported with a positive direct microscopic examination. We identified 83 patients with invasive disease An important fact is that we had 17 patients with suspicion of invasive aspergillosis, and that was ultimately confirmed by histologic examination; the speculation of colonization was confirmed by histology in another 9 pts These findings support the positive predictive value of the diagnostic algorithm

An important observation was that the majority of patients did have any hematological underlying disease. Underlying diseases were COPD, malnutrition, liver cirrhosis,…

When comparing both patient groups, we found that pts with invasive disease had a higher APACHE II score upon admission, that they experienced more hemodynamic instability and acute renal failure than pts considered colonized. An important difference between both pt groups in the outcome, with an in-hospital mortality of 77% in IA pts and 40% in colonized pts

Survival curves for ICU patients with IPA vs Aspergillus spp Survival curves for ICU patients with IPA vs Aspergillus spp. colonization …

Does Invasive Aspergillosis has an impact on ICU patient outcome? i.e.: is there an attributable mortality? Case-control study 1:2 matching Matching criteria APACHE II (admission) Diagnostic category Age Two cohorts of pts with same ‘expected mortality’ Vandewoude K. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of stay and ventilator dependence. J Hosp Infection 2004

An important question is whether invasive aspergillosis had an impact on outcome in terms of attributable mortality We tried to adress this issue a matched cohort study Pts were matched upon APACHE II score, age, and upon diagnostic category upon admission We found that hospital mortality was higher in the patient group with invasive disease, this was not significantly different, An important observation however is that the mortality in pts with IA was clearly higher than mortality as expected upon APACHE II score, in contrast to the data for the colonized pts. We also demonstrated that the use of ICU resources as significantly higher in pts with IA, as indicated by the difference in length of stay and ventilator dependence. Vandewoude K. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of stay and ventilator dependence. J Hosp Infection 2004

Conclusion Invasive Aspergillosis in ICU patient is a Fact … Incidence … 0.33 – 5.8% Depending on patient mix: MICU > SICU Limited patient groups, precluding firm conclusions … Underestimated? Delayed diagnosis Diagnosis post mortem … Grim prognosis Mortality exceeding 77% Observed mortality >> predicted mortality Attributable mortality … ? In conclusion, literature data indicate that invasive aspergillosis is an emerging disease in critically ill patients Data on incidence vary considerably, and are also influenced by type of hospital and type of ICU Proven IA is often an autopsy finding, indicating that diagnosis is delayed in most pts

Conclusion Do not discard an Aspergillus spp. positive respiratory tract specimen in critically ill patients – consider the clinical significance even in the absence of EORTC/MSG host risk factors

? Epidemiology: prospective multicenter observational studies needed to estimate incidence Biopsy if possible? Protocol based autopsy policy Validation of clinical diagnostic algorithm, Useful to guide (pre-emptive) therapy Development of criteria for pre-emptive treatment Consideration of additional host risk factors: COPD, steroid treatment, MOF, …. Explore and measure immunoparalytic state Evaluation of non-invasive serologic markers in ICU pts galactomannan Beta-D-glucan PCR